Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is an open label Phase II Trial that using the investigational anti-cancer agent,
Pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by
decreasing the size of the tumor or stopping its growth.